Healthy volunteers 20 years of age or older at the time of obtaining consent Patients with probably tau-mediated neuropsychiatric disorders 20 years of age or older at the time of obtaining consent Patients with ante-mortem conscent for autopsy 20 years of age or older at the time of obtaining consent
Conditions
Interventions
PET/MRI/psychological batteries/neurological examinations
PET/MRI/psychological batteries/neurological examinations
PET/MRI/psychological batteries/neurological examinations
Sponsors
National Institute of Radiological Sciences
Tokyo Metropolitan Geriatric Hospital National Center of Neurology and Psychiatry Mihara Memorial Hospital Fukushimura Hospital Nippon Medical School Hamamatsu University School of Medicine Osaka City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: healthy volunteer 1. 20 years of age or older at the time of obtaining consent. For the judgment of whether or not subject cognitive function can be deemed normal. 2. In order to reduce gender bias, subjects will be selected to match the male-to-female ratios of the patient groups to the maximum extent possible. 3. Healthy subjects who have the ability to consent to participate in this study, to read and understand the informed consent form. Patients with probably tau-mediated neuropsychiatric disorders Patients with ante-mortem consent for autopsy 1.Patients 20 years of age or older at the time of obtaining consent. 2.Details of inclusion criteria are determined separately in each center.
Exclusion criteria
Exclusion criteria: healthy volunteer 1. Subjects with organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2. Patients with substance-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study. 4. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.). 5. Subjects with tattoos. Subjects with claustrophobia. 6. Pregnant, possibly pregnant or lactating women. 7. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study. 8. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study. Patients with probably tau-mediated neuropsychiatric disorders Patients with ante-mortem consent for autopsy Details of exclusion criteria are determined separately in each center.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution volume SUV, and SUVR measured by positron emission tomography with [11C]PBB3 | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison among [11C]PBB3 PET, amyloid PET and clinical manifestations Comparison between [11C]PBB3 PET and histopathological findings | — |
Countries
Japan
Contacts
Public ContactKazuko SUZUKI
National Institute of Radiological Sciences Clinical Research Support Section
Outcome results
None listed